All questionsPharmacology: Dupixent (dupilumab) in atopic dermatitis5 questions · 2 sourcesMechanismIs Dupixent an immunosuppressant?“DUPIXENT is not an immunosuppressant and avoids broad immunosuppression1” (opens the source at this quote in a new tab)CopyFlag“It is unknown if DUPIXENT will influence the immune response against helminth infections1” (opens the source at this quote in a new tab)CopyFlag“Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor.” (opens the source at this quote in a new tab)CopyFlagNote: This is the manufacturer's statement; the Prescribing Information does not classify DUPIXENT as an immunosuppressant.How does Dupixent work in atopic dermatitis (mechanism of action)?“DUPIXENT binds to IL-4 receptor alpha, inhibiting IL-4 and IL-13 induced inflammatory responses1,2 The mechanism of dupilumab action has not been definitively established.” (opens the source at this quote in a new tab)CopyFlag“Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is Dupixent metabolized?“DUPIXENT is not metabolized through the liver or excreted through the kidneys1” (opens the source at this quote in a new tab)CopyFlag“The metabolic pathway of dupilumab has not been characterized. As a human monoclonal IgG4 antibody, dupilumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.” (opens the source at this quote in a new tab)CopyFlagNote: The first passage is the manufacturer's website statement; the Prescribing Information states that the metabolic pathway of dupilumab has not been characterized and that it is expected to be degraded in the same manner as endogenous IgG.How long does Dupixent stay in your system?“After the last steady-state dose of 300 mg QW, 300 mg Q2W, 200 mg Q2W, 300 mg Q4W, or 200 mg Q4W dupilumab, the median times to non-detectable concentration (<78 ng/mL) ranged from 9 to 13 weeks in adults and pediatric subjects 12 years of age and older. Population pharmacokinetic analyses indicate the median times to non-detectable concentration are approximately 1.5 times (up to 19 weeks) and 2.5 times (up to 32 weeks) longer in pediatric subjects 6 to 11 years of age and pediatric subjects 6 months to 5 years of age, respectively.” (opens the source at this quote in a new tab)CopyFlagNote: The Prescribing Information states times to non-detectable concentration and does not state a half-life.ComponentsWhat are the inactive ingredients in Dupixent?“Inactive ingredients: L-arginine hydrochloride, L-histidine, polysorbate 80, sodium acetate, sucrose, and water for injection.” (opens the source at this quote in a new tab)CopyFlag“Each 300 mg pre-filled syringe or pre-filled pen delivers 300 mg dupilumab in 2 mL which also contains L-arginine hydrochloride (10.5 mg), L-histidine (6.2 mg), polysorbate 80 (4 mg), sodium acetate (2 mg), sucrose (100 mg), and water for injection, pH 5.9. Each 200 mg pre-filled syringe or pre-filled pen delivers 200 mg dupilumab in 1.14 mL which also contains L-arginine hydrochloride (12 mg), L-histidine (3.5 mg), polysorbate 80 (2.3 mg), sodium acetate (1.2 mg), sucrose (57 mg), and water for injection, pH 5.9.” (opens the source at this quote in a new tab)CopyFlag